Five Years of Sacubitril/Valsartan—a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance

被引：0
|
作者：
Yee Soo Kim
Simerjeet Brar
Natalie D’Albo
Amit Dey
Sachin Shah
Sarju Ganatra
Sourbha S. Dani
机构：
[1] Lahey Hospital and Medical Center,Department of Internal Medicine
[2] Georgetown University Medical Center,Department of Internal Medicine
[3] Lahey Hospital and Medical Center,Beth Israel Lahey Health, Department of Cardiovascular Medicine
来源：
Cardiovascular Drugs and Therapy | 2022年 / 36卷
关键词：
Sacubitril/valsartan; FDA Adverse Event Reporting System; Real-world pharmacovigilance; Disproportionality analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：915 / 924
页数：9
相关论文
共 50 条
  • [41] A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system
    Wang, Yiwen
    Liu, Xuna
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [42] Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting
    Nordberg Backelin, Charlotte
    Fu, Michael
    Ljungman, Charlotta
    ESC HEART FAILURE, 2020, 7 (03): : 1049 - 1055
  • [43] REAL-WORLD IMPACT OF SACUBITRIL/VALSARTAN ON THE QUALITY OF LIFE OF HEART FAILURE PATIENTS IN PORTUGAL
    Afonso Nogueira, M.
    Afonso-Silva, M.
    Gomes, M.
    Andreozzi, V
    Vandewalle, B.
    Costa Ferreira, F.
    Monica, L.
    Cruz, L.
    Guimaraes, M.
    Proenca, G.
    VALUE IN HEALTH, 2020, 23 : S504 - S505
  • [44] Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience
    Monzo, L.
    Gaudio, C.
    Cicogna, F.
    Tota, C.
    Petronilli, V
    Mennuni, S.
    De Ruvo, E.
    Calo, L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (18) : 5690 - 5700
  • [45] PROJECTED HEALTH OUTCOMES WITH REAL-WORLD VERSUS OPTIMAL USAGE OF SACUBITRIL/VALSARTAN IN PORTUGAL
    Pardal, M.
    Machado, M.
    Guerreiro, T.
    Afonso-Silva, M.
    VALUE IN HEALTH, 2022, 25 (01) : S82 - S83
  • [46] The Real-World Price of Switching to an ARNI A Case for De Novo Sacubitril/Valsartan Initiation
    Page Ii, Robert L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (04) : 332 - 335
  • [47] Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience
    Monzo, L.
    Cicogna, F.
    Tota, C.
    Petronilli, V.
    Mennuni, S.
    De Ruvo, E.
    Calo, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 42 - 43
  • [48] Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience
    Monzo, Luca
    Ferrari, Ilaria
    Gaudio, Carlo
    Cicogna, Francesco
    Tota, Claudia
    Petronilli, Valentina
    Mennuni, Silvia
    De Ruvo, Ermenegildo
    Calo, Leonardo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
  • [49] Predictors of Sacubitril-Valsartan target dose achievement in a real-world population.
    Mariana Tinoco, M.
    Cardoso, F.
    Dias, G.
    Pereira, T.
    Faria, B.
    Almeida, F.
    Leite, S.
    Lourenco, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 111 - 111
  • [50] Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience
    Monzo, Luca
    Ferrari, Ilaria
    Gaudio, Carlo
    Cicogna, Francesco
    Tota, Claudia
    Petronilli, Valentina
    Mennuni, Silvia
    Ruvo, Ermenegildo De
    Calo, Leonardo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)
12345